Boehringer Ingelheim Pharmaceuticals, Inc (Docket No. 189-50)
released on December 29, 2017
found in newsletter: December 2017
The Attorney General, along with the attorneys general of all 50 states and the District of Columbia, reached a settlement with Boehringer Ingelheim Pharmaceuticals, Inc. (“BIPI”) regarding alleged off-label marketing and deceptive and misleading representations made in the promotion of four prescription drugs. Specifically, the States allege that BIPI: (1) misrepresented that its antiplatelet drug, Aggrenox®, was effective for many conditions “below the neck”, such as heart attacks and congestive heart failure, and that it was superior to Plavix® without evidence to substantiate that claim; (2) misrepresented that Micardis® protected patients from early morning strokes and heart attacks and treated metabolic syndrome; (3) misrepresented that Combivent® could be used as a first-line treatment for bronchospasms associated with chronic obstructive pulmonary disease (COPD); and (4) falsely stated that Atrovent® and Combivent® could be used at doses that exceeded the maximum dosage recommendation in the product labeling and that they were essential for treatment of COPD. The settlement requires BIPI to ensure that its marketing and promotional practices do not unlawfully promote these prescription drug products. Wyoming received $130,125.43 from the settlement.
Original Press Release